Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay.
An in vitro insulin glycation assay was developed for screening glycation inhibitors. The assay involves the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the formation of glycated insulin. The assay is simple, rapid and amenable for high throughput screening. Using this assay we have discovered a strong anti-glycation activity for the anti-tuberculosis drug rifampicin. These results were compared with bovine serum albumin glucose fluorescence assay. In addition, the IC(50) of rifampicin was lower than that of aminoguanidine, a known anti-glycating agent, suggesting that rifampicin is a more potent glycation inhibitor.
Golegaonkar
Sandeep B
SB
Council of Scientific and Industrial Reseach , India.
Bhonsle
Hermangi S
HS
Boppana
Ramanamurthy
R
Kulkarni
Mahesh J
MJ
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000737:chemistry* / Q000378:metabolism; D050260:Carbohydrate Metabolism; D002417:Cattle; D017127:Glycation End Products, Advanced / Q000737:chemistry* / Q000378:metabolism; D006031:Glycosylation; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000378:metabolism; D007328:Insulin / Q000031:analogs & derivatives / Q000032:analysis / Q000737:chemistry* / Q000378:metabolism; D012293:Rifampin / Q000031:analogs & derivatives / Q000737:chemistry* / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*
D000904:Antibiotics, Antitubercular; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D007328:Insulin; C039522:insulin, glycosylated; D012710:Serum Albumin, Bovine; D012293:Rifampin